share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4:持股变动声明
SEC announcement ·  03/12 17:49
Moomoo AI 已提取核心信息
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, engaged in multiple transactions involving the company's common stock between March 10, 2024, and March 12, 2024. Kasinger acquired a total of 7,750 shares through the exercise of derivative securities on March 10 and March 11. Subsequently, he sold 2,801 shares on March 11 at a price of $78.26 per share and 1,146 shares on March 12 at $74.44 per share, resulting in a total sale value of approximately $304,514.50. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics common stock amounted to 61,174 shares. The transactions are reported to be in progress.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, engaged in multiple transactions involving the company's common stock between March 10, 2024, and March 12, 2024. Kasinger acquired a total of 7,750 shares through the exercise of derivative securities on March 10 and March 11. Subsequently, he sold 2,801 shares on March 11 at a price of $78.26 per share and 1,146 shares on March 12 at $74.44 per share, resulting in a total sale value of approximately $304,514.50. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics common stock amounted to 61,174 shares. The transactions are reported to be in progress.
CRISPR Therapeutics总法律顾问兼秘书詹姆斯·卡辛格在2024年3月10日至2024年3月12日期间参与了多笔涉及公司普通股的交易。卡辛格于3月10日和3月11日通过行使衍生证券,共收购了7,750股股票。随后,他在3月11日以每股78.26美元的价格出售了2,801股股票,并于3月12日以每股74.44美元的价格出售了1,146股股票,总销售价值约为304,514.50美元。这些交易之后,卡辛格直接持有的CRISPR Therapeutics普通股为61,174股。据报告,交易正在进行中。
CRISPR Therapeutics总法律顾问兼秘书詹姆斯·卡辛格在2024年3月10日至2024年3月12日期间参与了多笔涉及公司普通股的交易。卡辛格于3月10日和3月11日通过行使衍生证券,共收购了7,750股股票。随后,他在3月11日以每股78.26美元的价格出售了2,801股股票,并于3月12日以每股74.44美元的价格出售了1,146股股票,总销售价值约为304,514.50美元。这些交易之后,卡辛格直接持有的CRISPR Therapeutics普通股为61,174股。据报告,交易正在进行中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息